Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.

Autor: Breugom AJ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Bastiaannet E; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands., Boelens PG; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Iversen LH; Department of Surgery, Aarhus University Hospital, Aarhus, Denmark., Martling A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Johansson R; Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden., Evans T; Public Health England, Birmingham, United Kingdom., Lawton S; Public Health England, York, United Kingdom., O'Brien KM; National Cancer Registry Ireland, Cork, Ireland., Van Eycken E; Belgian Cancer Registry, Brussels, Belgium., Janciauskiene R; Oncology Institute of Lithuanian University of Health Sciences, Kaunas, Lithuania., Liefers GJ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Cervantes A; Department of Haematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain., Lemmens VE; Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Eindhoven, The Netherlands; Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands., van de Velde CJ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: C.J.H.van_de_Velde@lumc.nl.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2016 Aug; Vol. 63, pp. 110-7. Date of Electronic Publication: 2016 Jun 11.
DOI: 10.1016/j.ejca.2016.04.017
Abstrakt: Background: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries.
Methods: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries.
Results: Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03).
Conclusion: The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.
(Copyright © 2016 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: